CasLoc logo
All Cases PTAB Litigations UPC Oppositions

Fresenius Kabi USA, LLC v. Mylan Laboratories Limited

1:15-cv-00185

Overview

Case Number 1:15-cv-00185
Filing Date 2015-10-19
Status Terminated
Termination Date 2016-07-11
Court District Court, N.D. West Virginia (wvnd)
Nature of Suit 830 Patent
Jurisdiction Type Federal Question
Cause of Action 35:271 Patent Infringement
Jury Demand None

Parties

Defendant

Mylan Laboratories Limited NPE (University / Research)

Represented By

0 Attorneys Listed
No attorneys available

Plaintiff

Fresenius Kabi USA, LLC Operating Company

Represented By

0 Attorneys Listed
No attorneys available

Court & Judges

Court

District Court, N.D. West Virginia (wvnd)

Global Patent Family Cross-Litigation Radar

CasLoc 360Β° Radar 5 Family Members

Multi-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions

πŸ‡ΊπŸ‡Έ
U.S. District Courts 1 proceeding
πŸ›οΈ
USPTO PTAB Trials Counterparts in force
πŸ‡ͺπŸ‡Ί
Unified Patent Court (UPC) Counterparts in force
πŸ‡©πŸ‡ͺ
European Patent Office (EPO) Counterparts in force
Worldwide Family Members (5): πŸ‡©πŸ‡ͺ Germany πŸ‡ΊπŸ‡Έ US 🌐 PCT
Parallel Proceedings Across Jurisdictions (1 found):
U.S. Courts: 1
U.S. District Court 2015-10-19
1:15-cv-00942

Fresenius Kabi USA, LLC v. Mylan Laboratories Limited

Asserted Patent
Status: DED
Stay ahead of cross-border rulings. Subscribe for free automated docket alerts across U.S. Courts, PTAB, UPC, and EPO.

Patents Involved

1 Patent

There is a single patent involved in this case.

Patent Asset Filing & Issue Date Expiration & Term Status External Links
US8118802
Connector for packaging containing medical fluids and packaging for medical fluids
Filed: 2010-08-18
Issued: 2012-02-21
Expired (Term Ended)
Expires: 2023-05-18

Patent Enforceability & Injunction Risk Assessment

Statutory Analysis
Injunction Viability (35 U.S.C. Β§ 283) Statutorily Barred

Statutorily Barred β€” Patent expired. Under 35 U.S.C. Β§ 283, injunctive relief is barred.

Terminal Disclaimer & Cellect Risk Low Risk

Standard Statutory Term β€” No obviousness-type double patenting noted.

Damages Lookback Horizon 6-Yr Max Lookback

Under 35 U.S.C. Β§ 286, damages cannot accrue for infringement prior to 6 years before filing. 4th & 8th Year Maintenance Fees Paid (12th Year Window Upcoming).

Procedural Motions & Interlocutory Orders

Motion Intelligence

Total Motions

36

Dispositive

0

Granted

25

Denied

0

Pending / Review

10

Motions by Category

Procedural / Extension Motion 28 Claim Construction / Markman Filing 8

Key Dispositive Motions & Rulings

Claim Construction / Markman Filing Granted
ORDER granting 69 Motion for Extension of Time to File. Opening Claim Construction Brief deadline is extended to 7/7/16; Deadline for answering claim constructi...
Entry #70 • 2016-06-24 Document →
Claim Construction / Markman Filing Granted
Joint MOTION for Extension of Time to File Opening Claim Construction Brief, Answering Claim Construction Brief and Joint Appendix of Intrinsic Evidence by Fres...
Entry #69 • 2016-06-23 Document →
Claim Construction / Markman Filing Pending / Under Review
ORDER; granting 66 Motion for Extension of Time to File. It is ORDERED that the June 16, 2016 deadline for the parties to submit the Opening Claim Construction ...
Entry #67 • 2016-06-14 Document →
Procedural / Extension Motion Pending / Under Review
MOTION for Extension of Time to File Joint Motion for Extension of Time by Fresenius Kabi Deutschland GMBH, Fresenius Kabi USA, LLC. (Attachments: # 1 Text of P...
Entry #66 • 2016-06-10 Document →
Claim Construction / Markman Filing Pending / Under Review
Other Document Final Joint Claim Construction Statement filed by Fresenius Kabi Deutschland GMBH, Fresenius Kabi USA, LLC. (Attachments: # 1 Exhibit 1- Joint Pr...
Entry #65 • 2016-06-09 Document →
Procedural / Extension Motion Granted
ORDER GRANTING UNOPPOSED MOTION TO AMEND COMPLAINT DKT. NO. 54 ; Court GRANTS the motion Dkt. No. 54 and DIRECTS the Clerk to file Fresenius amended complaint (...
Entry #63 • 2016-06-06 Document →

Docket Entries

(75 total)
Pleading / Complaint

COMPLAINT against Agila Specialties Inc., Mylan Inc., Mylan Laboratories Limited, Mylan Pharmaceuticals Inc., filed by Fresenius Kabi USA, LLC, Fresenius Kabi Deutschland GMBH. (Attachments: # 1 Exhibit A US Patent dated 11/9/2010, # 2 Exhibit B US Patent dated 12/28/2010, # 3 Exhibit C US Patent dated 2/21/2012, # 4 Exhibit D US Patent dated 4/24/2012, # 5 Civil Cover Sheet)(jmm) (Entered: 10/20/2015)

Entry #1 • 2015-10-19
1

Supplemental Information For Patent Cases Involving An Abbreviated New Drug Application (ANDA) filed by Fresenius Kabi Deutschland GMBH, Fresenius Kabi USA, LLC. (jmm) (Entered: 10/20/2015)

Entry #2 • 2015-10-19
1
Pleading / Complaint

REPORT to USPTO on the filing or determination of an action regarding re 1 Complaint. (jmm) (Entered: 10/20/2015)

Entry #3 • 2015-10-19
1

VERIFICATION OF ATTORNEY ADMISSION of Dary L. Wiesen, John T. Bennett, Samuel Sherry and Jennifer L. Ford via email. (jmm) (Entered: 10/20/2015)

Entry #4 • 2015-10-20
1

Filing fee: $ 400.00, receipt number WVNW001277. (jmm) (Entered: 10/21/2015)

Entry #5 • 2015-10-20
1

Track Case Updates

Automated email notifications for new filings & decisions

Identifier: •

Free service • 1-click unsubscribe anytime • Powered by CasLoc